- Home
- ROMA vs APLT Comparison
ROMA vs APLT Comparison
Compare ROMA & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROMA
- APLT
- Stock Information
- Founded
- ROMA 2018
- APLT 2016
- Country
- ROMA Hong Kong
- APLT United States
- Employees
- ROMA N/A
- APLT N/A
- Industry
- ROMA Savings Institutions
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ROMA Finance
- APLT Health Care
- Exchange
- ROMA Nasdaq
- APLT Nasdaq
- Market Cap
- ROMA 158.1M
- APLT 178.6M
- IPO Year
- ROMA 2024
- APLT 2019
- Fundamental
- Price
- ROMA $2.61
- APLT $0.26
- Analyst Decision
- ROMA
- APLT Buy
- Analyst Count
- ROMA 0
- APLT 5
- Target Price
- ROMA N/A
- APLT $4.13
- AVG Volume (30 Days)
- ROMA 12.1K
- APLT 24.8M
- Earning Date
- ROMA 12-15-2025
- APLT 11-13-2025
- Dividend Yield
- ROMA N/A
- APLT N/A
- EPS Growth
- ROMA N/A
- APLT N/A
- EPS
- ROMA N/A
- APLT N/A
- Revenue
- ROMA $1,568,345.00
- APLT $1,000,000.00
- Revenue This Year
- ROMA N/A
- APLT N/A
- Revenue Next Year
- ROMA N/A
- APLT $5,935.35
- P/E Ratio
- ROMA N/A
- APLT N/A
- Revenue Growth
- ROMA 23.21
- APLT N/A
- 52 Week Low
- ROMA $0.58
- APLT $0.22
- 52 Week High
- ROMA $4.66
- APLT $10.48
- Technical
- Relative Strength Index (RSI)
- ROMA 43.27
- APLT 27.74
- Support Level
- ROMA $2.53
- APLT $0.26
- Resistance Level
- ROMA $2.75
- APLT $0.40
- Average True Range (ATR)
- ROMA 0.10
- APLT 0.12
- MACD
- ROMA -0.02
- APLT -0.07
- Stochastic Oscillator
- ROMA 19.84
- APLT 4.83
About ROMA Roma Green Finance Limited
Roma Green Finance Ltd is principally engaged in the provision of ESG, corporate governance and risk management as well as sustainability and climate change-related advisory services. The company works closely with its clients to help them understand, identify, manage, and overcome various business matters arising from such factors related to ESG, sustainability and climate change. Geographically, the company generates its revenue from Hong Kong and Singapore.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.